Mr. Martin Schmieg
DIRECTOR
pharmaceutical industries
BriaCell
Canada
Biography
MR. MARTIN SCHMIEG, CPA, DIRECTOR OF THE BOARD Mr. Schmieg, with 35 years of business experience, is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries. As a hands-on leader, Mr. Schmieg’s early career focused on accounting and financial management responsibilities serving as Chief Financial Officer to privately held Cytometrics, Inc., Advanced Bionics Corporation and publicly traded Sirna Therapeutics, Inc. and Isolagen, Inc. In 2006, Mr. Schmieg assumed the position of Chief Executive Office of Freedom-2, Inc., a venture startup in novel dermatology applications. While at Freedom-2, Mr. Schmieg raised $14 million in venture capital and led the company in the development and market introduction of InfinitInk®, which was a Time Magazine “Invention of the Year” in 2008. In 2009, Mr. Schmieg reversed merged Freedom-2 into Nuvilex, Inc., now PharmaCyte, Inc.
Research Interest
Novel dermatology applications.